Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705520 · ClinicalTrials.gov registry record
Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 106
- Enrollment target
NCT03705520: Completed study, sponsored by Rush University Medical Center.
NCT03705520 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03705520 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the microbiome of medicated and non-medicated subjects diagnosed with Parkinson's disease. Where available, in comparison to the microbiome of a healthy spouse or 1st degree relative.
Primary Outcome
The investigators anticipate confirming their prior findings that patients with PD have dysbiosis, and further identifying the nature of the dysbiosis including changes at the species and strain level.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2018-05-05 |
| Est. Completion | 2023-05-31 |
What the finished NCT03705520 record still lists
NCT03705520 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03705520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03705520 about?
NCT03705520 is a clinical study titled "Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease". The purpose of this study is to evaluate the microbiome of medicated and non-medicated subjects diagnosed with Parkinson's disease. Where available, in comparison to the microbiome of a healthy spouse or 1st degree relative.
What is the current status of trial NCT03705520?
This trial is currently completed. The enrollment target is 106 participants. The study started on 2018-05-05. Estimated completion is 2023-05-31.
Who is sponsoring clinical trial NCT03705520?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI